Connect

Member Research and Reports

Member Research and Reports

Michigan Study Finds New Drug Cuts Risk of Deadly Transplant Disease in Half

A new study from the University of Michigan found that a class of drugs reduced the risk of patients contracting graft-vs.-host disease from bone marrow transplant treatments in half. Dr. Thomas Braun, professor of biostatistics, collaborated with others to analyze the effectiveness of this drug. The results appear in The Lancet Oncology. The drug, vorinostat, is already approved by the U.S. Food and Drug Administration, but researchers hypothesized that its anti-inflammatory effects demonstrated in laboratory studies could be useful in preventing graft-vs.-host disease, a condition in which the new donor cells begin attacking others cells in the patient’s body.